Separately, StockNews.com assumed coverage on shares of Pulse Biosciences in a research note on Saturday, September 17th. They set a sell rating on the stock.
Pulse Biosciences Stock Up 7.2 %
PLSE stock opened at $1.49 on Wednesday. Pulse Biosciences has a 12-month low of $1.18 and a 12-month high of $24.58. The company has a market cap of $55.32 million, a price-to-earnings ratio of -0.74 and a beta of 1.97. The company has a 50 day moving average of $1.58 and a two-hundred day moving average of $2.48.
Institutional Inflows and Outflows
Several hedge funds have recently modified their holdings of the business. Occudo Quantitative Strategies LP increased its stake in shares of Pulse Biosciences by 217.3% during the 2nd quarter. Occudo Quantitative Strategies LP now owns 58,383 shares of the company’s stock worth $54,000 after purchasing an additional 39,981 shares during the last quarter. Millennium Management LLC acquired a new position in Pulse Biosciences in the 2nd quarter valued at $184,000. TIAA FSB acquired a new position in Pulse Biosciences in the 2nd quarter valued at $42,000. Westside Investment Management Inc. grew its stake in Pulse Biosciences by 41.4% in the 2nd quarter. Westside Investment Management Inc. now owns 178,195 shares of the company’s stock valued at $272,000 after buying an additional 52,166 shares during the last quarter. Finally, Bank of America Corp DE grew its stake in Pulse Biosciences by 5.1% in the 1st quarter. Bank of America Corp DE now owns 820,390 shares of the company’s stock valued at $3,988,000 after buying an additional 39,645 shares during the last quarter. Institutional investors and hedge funds own 8.34% of the company’s stock.
About Pulse Biosciences
Pulse Biosciences, Inc operates as a novel bioelectric medicine company. It offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.
- Get a free copy of the StockNews.com research report on Pulse Biosciences (PLSE)
- The Worst May be Over for Target, But is the Stock Safe to Buy?
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- Two Fun Stocks The Insiders Are Buying
- Novavax Remains a Risk-On Stock in a Risk-Off Market
- 3 Defensive Stocks With 60-Year Dividend Hike Streaks
Receive News & Ratings for Pulse Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulse Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.